Article
Emergence of novel and dominant acquired EGFR solvent-front mutations at Gly796 (G796S/R) together with C797S/R and L792F/H mutations in one EGFR (L858R/T790M) NSCLC patient who progressed on osimertinib.
Lung cancer (Amsterdam, Netherlands) - 1 Jun 2017
Ou Sai-Hong Ignatius, Cui Jean, Schrock Alexa B, Goldberg Michael E, Zhu Viola W, Albacker Lee, Stephens Philip J, Miller Vincent A, Ali Siraj M
Abstract excerpt
Acquired epidermal growth factor receptor (EGFR) resistance mutations to osimertinib are common, including the EGFR C797S that abolishes the covalent binding of osimertinib to EGFR. Here we report the emergence of novel EGFR solvent front mutations at Gly796 (G796S/R) in addition to a hinge pocket L792F/H mutations, and C797S/G all in cis with T790M in a single patient on progression on osimertinib as detected by...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.